Helicobacter Infections Clinical Trial
Official title:
Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy: Prospective Validation
H. pylori infection is the most important causative agent of gastritis, and subsequent atrophic gastritis. The endoscopic diagnosis of H. pylori infection relies on urease tests such as the Clo test. However, treatment with proton pump inhibitors (PPI) impairs the diagnostic yeld of urease tests. The EndoFaster test (NISO BioMed, Turin, Italy) is a new technology that has the advantage, over conventional urease tests, of a real-time analysis of the gastric juice that can provide information regarding Helicobacter pylori infection and pH value of the gastric contents. A well designed clinical study is therefore warranted to fully assess the performance of the EndoFaster test in detecting H. pylori infection in patients treated with PPI. We aim to perform a clinical study in an adult population in United Kingdom in order to determine the diagnostic accuracy of the Endo Faster test compared to the Clo test, histological diagnosis and the faecal antigen test in evaluating H.pylori infection. Patients on PPI will undergo a gastroscopy with multiple biopsies and during the exam NISO Biomed EndoFaster test, as well as the Clo test, will be carried out. H. pylori faecal antigen test will also be performed and used as gold standard. Diagnostic accuracy of the different methods will be determined.
Urease tests such as the Clo test for the diagnosis of Helicobacter pylori infection have
been widely used because they are simple, cheap, and easy to carry out (1, 2). They can be
performed during the endoscopic exam and give a relatively rapid result. However, treatment
with proton pump inhibitors (PPI) may alter the result by changing the milieu where bacteria
are present, especially in the antrum, by rendering it inhospitable with consequent decrease
in the bacterial load. In addition, PPI themselves may have antiurease properties (3).
Another reason for a false-negative result is the presence of intestinal metaplasia (4),
which also corresponds to an inhospitable environment for Helicobacter pylori. EndoFaster
test is a new technology that has the advantage, over conventional urease tests, of a
real-time analysis of the gastric juice that can provide information regarding Helicobacter
pylori infection and pH value of the gastric contents. Sensitivity, specificity, PPV and NPV
of EndoFaster test for Helicobacter pylori infection resulted to be 98.5%, 87.6%, 84.4% and
98.8 %, respectively. This test may be more accurate than conventional urease tests in the
diagnosis of Helicobacter pylori infection in subjects on PPI as indeed it should increase
the analysed area, thereby allowing to evaluating the bacterial density in both the gastric
antrum and corpus. No data are currently available about the performance of the EndoFaster
test in subjects on PPI and a well-designed clinical study is warranted.
The main aim of our study is to conduct a comparative study with the NISO BioMed EndoFaster
test, the urease-based test (Clo test), histologic diagnosis and the faecal antigen test
(used as the gold standard) for the diagnosis of Helicobacter pylori infection in
PPI-treated patients.
We will perform a clinical study using the NISO BioMed Endofaster test to diagnose
Helicobacter pylori infection in patients on PPI therapy. The study will be conducted as a
collaboration between NISO BioMed (Turin, Italy) and Homerton University Hospital (London,
UK). The study will be performed at the Homerton Hospital.
One hundred patients on PPI will be enrolled among the patients with dyspepsia referred for
gastroscopy at Homerton University Hospital (London, United Kingdom). A control group of 50
patients with dyspepsia, not on PPI, will be also enrolled in the study.
On the day of the endoscopic procedure the patients will bring a stool sample for the
detection of Helicobacter pylori antigen. Subsequently, a gastroscopy with multiple biopsies
will be performed and during the exam NISO Biomed EndoFaster test, as well as the Clo test,
will be carried out.
Directed biopsies will be collected from the antrum and corpus, following the protocol of
the Operative Link for Gastritis Assessment (OLGA) and Sydney classifications for chronic
gastritis. Biopsies will be examined at the Pathology laboratory of University College
London Hospital and interpreted using the OLGA staging system as well as the Sydney system
for the classification of gastritis (5-8).
The performance of the EndoFaster test for the diagnosis of Helicobacter pylori infection
will be compared to the Clo test, the histologic diagnosis and the faecal antigen test. In
particular, statistical analyses will consist of calculations of the performance indicators
of the EndoFaster test, including ROC analysis for cut-off values that give the optimal
sensitivity/specificity balance.
The principal goal of this clinical study is to establish the performance of the EndoFaster
test in detecting the Helicobacter pylori infection rate in the study population. For this
endpoint, we will calculate sensitivity (SE), specificity (SP), negative predictive value
(NPV), positive predictive value (PPV) and AUC (area under ROC curve), collectively and
individually for each 4 tests. ROC analysis can be used to estimate the best SE/SP balance
for each single test. One of the aims is to establish the best cut-offs in order to give the
EndoFaster test an optimal performance.
Additionally, clinically significant conditions (gastric atrophy, intestinal metaplasia,
gastric cancer) will be recorded and the association rate with Helicobacter pylori infection
will be studied (9,10).
The necessary preparations for the study execution at Homerton University Hospital NHS
Foundation Trust will start immediately when the hospital has reached the agreement with
NISO BIOMED. The study plan necessitates a review by the institutional review board (IRB,
Ethical Committee) before permission to start.
We aim to obtain unbiased (i.e., 100% confirmed by the gold standard, i.e. faecal antigen
test) estimate for the performance of EndoFaster test in detecting the Helicobacter pylori
infection rate in patients on PPI treatment. This will include determining the optimal
cut-offs that give the optimal SE/SP balance for detecting the study endpoint. Application
of these cut-offs in clinical practice would lead to optimised performance of EndoFaster
test.
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00723502 -
Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients
|
Phase 2 | |
Recruiting |
NCT03365609 -
A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children
|
N/A | |
Completed |
NCT00005496 -
Inflammation, Infection, and Future Cardiovascular Risk
|
N/A | |
Completed |
NCT01219764 -
A Trial of Standard vs Half Dose Rabeprazole, Clarithromycin, Metronidazole and Amoxicillin in the Treatment of Helicobacter Pylori Infection
|
Phase 4 | |
Completed |
NCT00216450 -
Study of the Safety and Effectiveness of Rabeprazole in Treatment of Helicobacter Pylori Infection in Adults.
|
Phase 4 | |
Completed |
NCT00212225 -
Risk Factors for Gastric Disease in Pediatric Helicobacter Pylori (H. Pylori)
|
N/A | |
Completed |
NCT00083291 -
Helicobacter Pylori and Dry Eye
|
N/A | |
Not yet recruiting |
NCT04652284 -
Effectiveness of Rifabutin for Treatment of Helicobacter Pylori
|
Phase 3 | |
Completed |
NCT02449941 -
Helicobacter Pylori and Proton Pump Inhibitor
|
N/A | |
Completed |
NCT02395458 -
Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens
|
Phase 4 | |
Completed |
NCT00194688 -
Breath Ammonia Method for H. Pylori Detection: Phase II
|
Phase 2 | |
Active, not recruiting |
NCT01133951 -
Helicobacter Pylori Eradication to Prevent Gastric Cancer
|
N/A | |
Completed |
NCT00669955 -
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
|
Phase 3 | |
Completed |
NCT00816140 -
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
|
Phase 4 | |
Completed |
NCT00490386 -
Helicobacter Pylori and Acute Alcohol Induced Pancreatitis
|
N/A | |
Withdrawn |
NCT02645201 -
The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children
|
N/A | |
Terminated |
NCT00664209 -
Treating H. Pylori in Parkinson's Patients With Motor Fluctuations
|
Phase 3 | |
Completed |
NCT01922505 -
Eradication Rates of Helicobacter Pylori and Its Affecting Factors
|
Phase 4 | |
Completed |
NCT01792700 -
Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy
|
Phase 4 | |
Completed |
NCT02970110 -
Specimen Collection Study for H. Pylori Testing
|